ALK and non-small cell lung carcinoma: Two phase III studies (J-ALEX and ALEX) comparing alectinib and crizotinib for ALK-p, ALK-inhibitor-naïve, advanced NSCLC showed that alectinib significantly increased progression-free survival (PFS) compared to crizotinib [19,20].